NexImmune (NASDAQ:NEXI – Get Rating) announced its earnings results on Thursday. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.70) by $0.04, MarketWatch Earnings reports.
Shares of NASDAQ NEXI traded down $0.01 on Friday, reaching $2.01. 331,685 shares of the company traded hands, compared to its average volume of 155,070. NexImmune has a fifty-two week low of $1.72 and a fifty-two week high of $19.50. The company has a 50 day moving average of $2.84 and a 200 day moving average of $4.56.
A number of analysts have weighed in on the stock. Barclays raised their price objective on shares of NexImmune from $4.00 to $7.00 and gave the stock an “overweight” rating in a report on Friday, April 1st. Raymond James lowered their price objective on shares of NexImmune from $21.00 to $13.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 22nd. Zacks Investment Research upgraded shares of NexImmune from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a research report on Thursday, February 24th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of NexImmune in a research report on Friday, April 1st.
Several hedge funds and other institutional investors have recently modified their holdings of NEXI. Morgan Stanley acquired a new stake in shares of NexImmune in the first quarter valued at $493,000. PNC Financial Services Group Inc. raised its position in shares of NexImmune by 566.8% in the first quarter. PNC Financial Services Group Inc. now owns 111,882 shares of the company’s stock valued at $471,000 after purchasing an additional 95,104 shares during the period. Renaissance Technologies LLC raised its position in shares of NexImmune by 44.7% in the first quarter. Renaissance Technologies LLC now owns 73,661 shares of the company’s stock valued at $310,000 after purchasing an additional 22,761 shares during the period. American International Group Inc. raised its position in shares of NexImmune by 155.1% in the third quarter. American International Group Inc. now owns 9,662 shares of the company’s stock valued at $146,000 after purchasing an additional 5,875 shares during the period. Finally, Wells Fargo & Company MN raised its position in shares of NexImmune by 266.4% in the second quarter. Wells Fargo & Company MN now owns 7,343 shares of the company’s stock valued at $120,000 after purchasing an additional 5,339 shares during the period. Institutional investors and hedge funds own 58.40% of the company’s stock.
About NexImmune (Get Rating)
NexImmune, Inc, a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform.
- Get a free copy of the StockNews.com research report on NexImmune (NEXI)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for NexImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NexImmune and related companies with MarketBeat.com's FREE daily email newsletter.